Oral semaglutide vs Orforglipron
The two GLP-1s you can swallow. One is a peptide with food and water rules, the other a small molecule with none — and their records are not the same size.
Short answer
On weight loss, oral semaglutide comes out ahead, with 15.1% at 68 weeks in OASIS 1 against 11.2% at 72 weeks in ATTAIN-1 for orforglipron. Those figures come from separate trials, not a head-to-head study. Both are FDA-approved. The table below compares their FDA status, route, headline human result and main safety signal side by side.
Oral semaglutide
Rybelsus, Wegovy pill
The first oral GLP-1 — approved for type-2 diabetes on the PIONEER program (as Rybelsus) and, since December 2025, for chronic weight management and cardiovascular risk reduction at a higher 25 mg dose (as the Wegovy pill).
Full Oral semaglutide evidence reviewOrforglipron
~11% in ATTAIN-1; a scalable oral pill whose appeal is access, not peak efficacy. FDA-approved for weight management (Foundayo, 2026) — the type-2 diabetes indication is still under review.
Full Orforglipron evidence reviewOral semaglutide vs Orforglipron: head to head
- FDA status / approved use
Oral semaglutide
Approved as Rybelsus for type 2 diabetes; an oral version was FDA-approved for weight loss in December 2025Orforglipron
FDA-approved April 2026 as Foundayo for chronic weight management; diabetes indication still under review- Marketed for
Oral semaglutide
Type-2 diabetes, weight lossOrforglipron
Weight loss, type-2 diabetes- Outcome areas
Oral semaglutide
Blood sugar / insulin sensitivityOrforglipron
Weight loss / appetite; Blood sugar / insulin sensitivity- Evidence grade
Oral semaglutide
FDA-approvedOrforglipron
FDA-approved- How it works
Oral semaglutide
GLP-1 receptor agonist absorbed through the stomach with the help of the enhancer SNACOrforglipron
Small-molecule, non-peptide GLP-1 receptor agonist that survives digestion- Route and dosing
Oral semaglutide
Oral tablet, once daily (Wegovy pill label); maintenance 25 mg once dailyOrforglipron
Oral tablet, once daily (Foundayo label); maintenance 5.5 mg or higher once daily, by response and tolerability- Headline human result
Oral semaglutide
15.1% mean weight loss vs 2.4% on placebo at 68 weeks (OASIS 1, 50 mg daily)Orforglipron
11.2% mean weight loss vs 2.1% on placebo at 72 weeks (ATTAIN-1, 36 mg daily)- Strongest evidence
Oral semaglutide
PIONEER 1, JAMA 2019Oral semaglutide evidence reviewPubMed 31186300Orforglipron
ATTAIN-1, NEJM 2025Orforglipron evidence reviewPubMed 40960239- Key safety signal
Oral semaglutide
Gastrointestinal side effects similar to other GLP-1 drugs; cardiovascular safety cleared in PIONEER 6Orforglipron
Dose-related nausea, vomiting and diarrhea; no long-term cardiovascular or renal outcomes trial yet- How it is obtained
Oral semaglutide
Prescription. Manufacturer self-pay for Wegovy (oral pill) runs $149–$299 per fill, against a $1,349 list priceWegovy cost breakdownOrforglipron
Prescription drug
| Oral semaglutide | Orforglipron | |
|---|---|---|
| FDA status / approved use | Approved as Rybelsus for type 2 diabetes; an oral version was FDA-approved for weight loss in December 2025 | FDA-approved April 2026 as Foundayo for chronic weight management; diabetes indication still under review |
| Marketed for | Type-2 diabetes, weight loss | Weight loss, type-2 diabetes |
| Outcome areas | Blood sugar / insulin sensitivity | Weight loss / appetite; Blood sugar / insulin sensitivity |
| Evidence grade | FDA-approved | FDA-approved |
| How it works | GLP-1 receptor agonist absorbed through the stomach with the help of the enhancer SNAC | Small-molecule, non-peptide GLP-1 receptor agonist that survives digestion |
| Route and dosing | Oral tablet, once daily (Wegovy pill label); maintenance 25 mg once daily | Oral tablet, once daily (Foundayo label); maintenance 5.5 mg or higher once daily, by response and tolerability |
| Headline human result | 15.1% mean weight loss vs 2.4% on placebo at 68 weeks (OASIS 1, 50 mg daily) | 11.2% mean weight loss vs 2.1% on placebo at 72 weeks (ATTAIN-1, 36 mg daily) |
| Strongest evidence | PIONEER 1, JAMA 2019Oral semaglutide evidence reviewPubMed 31186300 | ATTAIN-1, NEJM 2025Orforglipron evidence reviewPubMed 40960239 |
| Key safety signal | Gastrointestinal side effects similar to other GLP-1 drugs; cardiovascular safety cleared in PIONEER 6 | Dose-related nausea, vomiting and diarrhea; no long-term cardiovascular or renal outcomes trial yet |
| How it is obtained | Prescription. Manufacturer self-pay for Wegovy (oral pill) runs $149–$299 per fill, against a $1,349 list priceWegovy cost breakdown | Prescription drug |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- FDA-approved:
- Approved by the FDA for a defined indication, on the strength of pivotal human trials.
Our verdict
Both are FDA-approved, so the choice is about what each has actually proven. Oral semaglutide came through the PIONEER program for type-2 diabetes as Rybelsus and, since December 2025, is approved at 25 mg for chronic weight management and cardiovascular risk reduction as the Wegovy pill — the deeper record of the two. Orforglipron reported about 11% weight loss in ATTAIN-1 and was approved for weight management in 2026 as Foundayo, with its type-2 diabetes indication still under review; being a non-peptide small molecule, it carries no food or water timing rules. The two have not been compared head to head.
Oral semaglutide fits if
You want the oral GLP-1 with the longer record, including cardiovascular risk reduction, and the dosing rules are manageable for you.
Orforglipron fits if
The dosing rules are the obstacle, and a daily tablet with no food or water timing is worth a shallower evidence record.
Oral semaglutide vs Orforglipron: common questions
- Are oral semaglutide and orforglipron both FDA-approved?
- Yes. Oral semaglutide is approved as Rybelsus for type 2 diabetes; an oral version was FDA-approved for weight loss in December 2025. Orforglipron was FDA-approved in April 2026 as Foundayo for chronic weight management; diabetes indication still under review.
- Which has stronger human evidence, oral semaglutide or orforglipron?
- Neither clearly. Both have approval-level evidence. The key source for oral semaglutide is PIONEER 1, JAMA 2019; for orforglipron, it is ATTAIN-1, NEJM 2025.
- What are the main safety concerns with oral semaglutide and orforglipron?
- For oral semaglutide, watch for gastrointestinal side effects similar to other GLP-1 drugs; cardiovascular safety cleared in PIONEER 6. For orforglipron, watch for dose-related nausea, vomiting and diarrhea; no long-term cardiovascular or renal outcomes trial yet.
Key studies behind each
Oral semaglutide
- Aroda VR, Rosenstock J, Terauchi Y, et al. (2019). PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. PubMed 31186300
- Pratley R, Amod A, Hoff ST, et al. (2019). Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. PubMed 31186120
- Husain M, Birkenfeld AL, Donsmark M, et al. (2019). Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6). N Engl J Med. PubMed 31185157
- Knop FK, Aroda VR, do Vale RD, et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. PubMed 37385278
Orforglipron
- Frias JP, Hsia S, Eyde S, et al. (2023). Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. PubMed 37369232
- Wharton S, et al. (2025). Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with cardiometabolic improvements. Cardiovasc Diabetol. PubMed 40481478
- Rosenstock J, Frias JP, Rodbard HW, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. PubMed 40544435
- Wharton S, Aronne LJ, Wadden TA, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. PubMed 40960239
The full evidence reviews
- Oral semaglutide (Rybelsus): what the PIONEER trials actually showed
A GLP-1 peptide in a pill is hard to pull off. PIONEER 1, 4, and 6 plus OASIS 1 — read straight from the primary literature.
Updated September 2026
- Orforglipron: the oral non-peptide GLP-1, and what the trials actually show
A once-daily small-molecule GLP-1 pill with no food restrictions — from Phase 2 proof of concept to the Phase 3 read-outs. The evidence, graded.
Updated August 2026